Moreover, a recent phase I/II trial (NCT02061332) involving 58 HER2-positive ductal carcinoma in situ (DCIS) patients validated the feasibility of DC-based vaccination and assessed different DC delivery methods [21]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.